DIM-C

DIM-C (C-substituted diindolylmethane) is a synthetic derivative of 3,3'-diindolylmethane (DIM) designed to act as a potent ligand for nuclear receptors, most notably the peroxisome proliferator-activated receptor gamma (PPARγ). Developed primarily by researchers at Texas A&M University, DIM-C compounds are chemically modified at the central bridging carbon atom to enhance the pharmacological properties and potency of natural DIM, a metabolite of indole-3-carbinol. In preclinical oncology research, DIM-C has demonstrated significant anti-tumor activity across various malignancies, including bladder, breast, and pancreatic cancers. Specifically, in bladder cancer models, DIM-C has been shown to sensitize tumors to EGFR inhibition (e.g., gefitinib) by upregulating PPARγ expression and promoting its nuclear accumulation, thereby overcoming resistance to targeted therapies. These compounds function by inducing apoptosis and inhibiting cell cycle progression through the modulation of PPARγ-dependent signaling pathways.

Other names

C-substituted diindolylmethaneC-substituted DIM